Anti-JAM2 antibody

Anti-JAM2 antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Rabbit Polyclonal to Human JAM2

IHC-P

Human Junctional Adhesion Molecule B

JAM-2 antibody; JAM-B antibody; Jcam2 antibody; VE-JAM antibody; 1110002N23Rik antibody; 2410030G21Rik antibody; 2410167M24Rik antibody; JAMB antibody; CD322 antibody; JAM-B antibody; VEJAM antibody; PRO245 antibody; VE-JAM antibody; C21orf43 antibody; 2410167M24Rik antibody; AU016127 antibody; 1110002N23Rik antibody; 2410030G21Rik antibody; C21orf43 antibody; CD322 antibody; JAM2 antibody; JAM-2 antibody; JAM-2 antibody; JAMB antibody; JAM-B antibody; JAM-B antibody; JAM-IT/VE-JAM antibody; Jcam2 antibody; PRO245 antibody; RP23-253E17.2 antibody; UNQ219/PRO245 antibody; VEJAM antibody; VE-JAM antibody; VE-JAM antibody

Rabbit IgG

Produced in rabbits immunized with a synthetic peptide corresponding to the center region of the Human Junctional Adhesion Molecule B, and purified by antigen affinity chromatography.

Polyclonal

0.2 μm filtered solution in PBS

This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

Junctional adhesion molecule B (JAM-B), also known as Junctional adhesion molecule 2 (JAM2), Vascular endothelial junction-associated molecule (VE-JAM), and CD322, is a single-pass type I membrane protein which belongs to the immunoglobulin superfamily. It is prominently expressed on high endothelial venules. expression to be restricted to the high endothelial venule of tonsil and lymph nodes. The localization to the endothelium of arterioles in and around inflammatory and tumor foci. JAM-B can function as an adhesive ligand for the T cell line J45 and can interact with GM-CSF/IL-4-derived peripheral blood dendritic cells, circulating CD56(+) NK cells, circulating CD56(+)CD3(+) NK/T cells, and circulating CD56(+)CD3(+)CD8(+) cytolytic T cells. JAM-2 is expressed on high endothelial venules (HEVs) in human tonsil and on a subset of human leukocytes, suggesting that JAM-2 plays a central role in the regulation of transendothelial migration. It binds to very late activation antigen (VLA)-4, a leucocyte integrin that contributes to rolling and firm adhesion of lymphocytes to endothelial cells through binding to vascular cell adhesion molecule (VCAM)-1. JAM-B appears to contribute to leucocyte extravasation by facilitating not only transmigration but also rolling and adhesion. JAM-B acts as an adhesive ligand for interacting with a variety of immune cell types and may play a role in lymphocyte homing to secondary lymphoid organs.